NICE

NICE plays a pivotal role in supporting the adoption of biosimilars in the UK by ensuring they are evaluated and recommended within the same framework as their reference biologics. According to NICE's position statement, if guidance exists for a reference biological medicine, it also applies to its biosimilar counterpart.

This approach reinforces clinical confidence by affirming that biosimilars are expected to be just as safe and effective as the originator products. NICE's technology appraisal guidance often advises that, when multiple treatments are suitable, the least expensive option should be chosen – factoring in administration costs, dosage and product pricing. This frequently positions biosimilars as the preferred choice, helping the NHS achieve better value for money.

Beyond guidance, NICE's endorsement of biosimilars has helped normalise their use across the UK healthcare system. By treating biosimilars as distinct but equivalent medicines, NICE encourages prescribers to consider them without bias, promoting broader access to biologic therapies. This has been especially impactful in therapeutic areas like rheumatology and oncology, where biosimilars have enabled thousands of additional patients to receive treatment.

NICE's consistent messaging and integration of biosimilars into its appraisal processes have contributed to the UK's growing biosimilar market, aligning clinical practice with cost-effective prescribing strategies.